成人T细胞急性淋巴细胞白血病复发后预后不佳。由于早期 T 细胞前体亚型表现出与急性髓系白血病相似的特征，例如表观遗传失调，因此低甲基化剂可能会引起人们的兴趣。我们描述了一位患者在同种异体干细胞移植后 3 个月后病情复发的病例，他在阿扎胞苷治疗后获得完全缓解，并在 9 年后仍在接受治疗。我们讨论了这种长期反应的生物学背景，强调了低甲基化药物的免疫作用，以及低甲基化药物与其他药物（如维奈托克）联合使用所开辟的前景。

Adult T-cell acute lymphoblastic leukemia has a poor outcome after relapse. Because the subtype of early T-cell precursor displays characteristics close of those of acute myeloid leukemia, such as epigenetic dysregulation, hypomethylating agents might prove of interest. We describe the case of a patient relapsing 3 months only after allogeneic stem cell transplantation who achieved complete remission on azacitidine, and is still on therapy 9 years later. We discuss the biological background of this very long-term response, underlining the immunological effects of hypomethylating agents, and the perspectives opened by combination of hypomethylating agents with other drugs such as venetoclax.